S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
NYSE:EBS

Emergent BioSolutions (EBS) Stock Price, News & Analysis

$2.04
+0.18 (+9.68%)
(As of 04/19/2024 ET)
Today's Range
$1.84
$2.06
50-Day Range
$1.53
$3.41
52-Week Range
$1.42
$10.88
Volume
936,801 shs
Average Volume
991,285 shs
Market Capitalization
$106.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Emergent BioSolutions MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
145.1% Upside
$5.00 Price Target
Short Interest
Bearish
11.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.40
Upright™ Environmental Score
News Sentiment
0.66mentions of Emergent BioSolutions in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($13.98) to ($0.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.83 out of 5 stars

Medical Sector

241st out of 909 stocks

Pharmaceutical Preparations Industry

99th out of 424 stocks

EBS stock logo

About Emergent BioSolutions Stock (NYSE:EBS)

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

EBS Stock Price History

EBS Stock News Headlines

Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Emergent BioSolutions Shares Drop on S&P Downgrade
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Q4 2023 Emergent BioSolutions Inc Earnings Call
Emergent BioSolutions: Q4 Earnings Insights
Emergent BioSolutions's Earnings: A Preview
Biotech with Baltimore facility taps new CEO
Why Is Emergent BioSolutions (EBS) Stock Up 70% Today?
Why Is Emergent BioSolutions (EBS) Stock Up 70% Today?
See More Headlines
Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
4/21/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
CUSIP
29089Q10
Employees
1,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+145.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-760,500,000.00
Pretax Margin
-69.68%

Debt

Sales & Book Value

Annual Sales
$1.05 billion
Cash Flow
$0.88 per share
Book Value
$12.51 per share

Miscellaneous

Free Float
51,396,000
Market Cap
$106.88 million
Optionable
Optionable
Beta
1.20
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Richard S. Lindahl M.B.A.Mr. Richard S. Lindahl M.B.A. (Age 60)
    Executive VP, CFO & Treasurer
    Comp: $799.38k
  • Ms. Jennifer L. Fox
    Executive VP of External Affairs, General Counsel & Corporate Secretary
  • Mr. Joseph C. Papa Jr. (Age 68)
    CEO & President
  • Mr. Robert G. Burrows
    Vice President of Investor Relations
  • Ms. Coleen Glessner
    Executive Vice President of Global Quality and Ethics & Compliance
  • Michelle Pepin
    Senior VP & Chief Human Resource Officer
  • Ms. Stephanie Duatschek
    Senior VP, Chief Strategy & Transformation Officer
  • Dr. Kelly Lyn Warfield
    Senior VP of Science & Development
  • Mr. Paul A. Williams
    Senior Vice President of Products Business
  • William Hartzel
    Senior Vice President of Manufacturing & Bioservices

EBS Stock Analysis - Frequently Asked Questions

Should I buy or sell Emergent BioSolutions stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares.
View EBS analyst ratings
or view top-rated stocks.

What is Emergent BioSolutions' stock price target for 2024?

2 Wall Street analysts have issued 1-year target prices for Emergent BioSolutions' stock. Their EBS share price targets range from $5.00 to $5.00. On average, they expect the company's share price to reach $5.00 in the next year. This suggests a possible upside of 145.1% from the stock's current price.
View analysts price targets for EBS
or view top-rated stocks among Wall Street analysts.

How have EBS shares performed in 2024?

Emergent BioSolutions' stock was trading at $2.40 at the beginning of 2024. Since then, EBS stock has decreased by 15.0% and is now trading at $2.04.
View the best growth stocks for 2024 here
.

Are investors shorting Emergent BioSolutions?

Emergent BioSolutions saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,700,000 shares, an increase of 16.1% from the March 15th total of 4,910,000 shares. Based on an average trading volume of 2,980,000 shares, the days-to-cover ratio is presently 1.9 days. Approximately 11.4% of the company's shares are sold short.
View Emergent BioSolutions' Short Interest
.

When is Emergent BioSolutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our EBS earnings forecast
.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) released its quarterly earnings data on Wednesday, March, 6th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by $0.44. The biopharmaceutical company earned $276.60 million during the quarter, compared to the consensus estimate of $247.63 million. Emergent BioSolutions had a negative net margin of 72.11% and a negative trailing twelve-month return on equity of 37.35%. During the same quarter in the previous year, the firm posted ($0.31) EPS.

What ETF holds Emergent BioSolutions' stock?

Amplify Treatments, Testing and Advancements ETF holds 12,240 shares of EBS stock, representing 0.27% of its portfolio.

What guidance has Emergent BioSolutions issued on next quarter's earnings?

Emergent BioSolutions issued an update on its first quarter 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $200.0 million-$250.0 million, compared to the consensus revenue estimate of $185.4 million.

What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?

38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

Who are Emergent BioSolutions' major shareholders?

Emergent BioSolutions' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.37%) and SeaCrest Wealth Management LLC (0.18%). Insiders that own company stock include Kathryn C Zoon, Richard S Lindahl and Ronald Richard.
View institutional ownership trends
.

How do I buy shares of Emergent BioSolutions?

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:EBS) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners